The roles of anthrax toxin in pathogenesis

Current Opinion in Microbiology

Volumn 7, Issue 1, 2004, Pages 19-24

  Moayeri, Mahtab ^a   Leppla, Stephen H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; GAMMA INTERFERON; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; KINESIN; LIPOPOLYSACCHARIDE; PROTEINASE; SYNAPTOPHYSIN; TARGET OF RAPAMYCIN KINASE; TOXIN ANTIBODY; TUMOR NECROSIS FACTOR;

ANTHRAX; APOPTOSIS; BACILLUS ANTHRACIS; BACTEREMIA; BACTERIAL GROWTH; BACTERIAL SPORE; BACTERIAL SURVIVAL; CELL ACTIVATION; CELL DEATH; CYTOLYSIS; DENDRITIC CELL; GENE LOCUS; GENE MAPPING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; IMMUNE RESPONSE; LETHALITY; LYMPH NODE; MACROPHAGE; NONHUMAN; OPSONIZATION; PATHOGENESIS; PHAGOCYTOSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SENSITIZATION; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SPORE GERMINATION; VACCINATION;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 1242351553     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2003.12.001     Document Type: Review

References (71)

1. Collier R.J., Young J.A. Anthrax toxin. Annu Rev Cell Dev Biol. 19:2003;45-70.
2. Leppla SH: Anthrax toxin. In Bacterial Protein Toxins, edn 1. Edited by Aktories K, Just I. Berlin: Springer; 2000:445-472.
3. Fish D.C., Klein F., Lincoln R.E., Walker J.S., Dobbs J.P. Pathophysiological changes in the rat associated with anthrax toxin. J Infect Dis. 118:1968;114-124.
4. Klein F., Dean R., Hodges D.R., Mahlanadat B.G., Jones W.I., Haines B.W., Lincoln R. Anthrax toxin: causative agent in the death of rhesus monkeys. Science. 138:1962;1331-1333.
5. Moayeri M., Haines D., Young H.A., Leppla S.H. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest. 112:2003;670-682 The first extensive pathology and cytokine-based investigation of how lethal toxin kills mice.
6. Pezard C., Berche P., Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun. 59:1991;3472-3477.
7. Pezard C., Duflot E., Mock M. Construction of Bacillus anthracis mutant strains producing a single toxin component. J Gen Microbiol. 139:1993;2459-2463.
8. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature. 385:1997;833-838.
9. Pannifer A.D., Wong T.Y., Schwarzenbacher R., Renatus M., Petosa C., Bienkowska J., Lacy D.B., Collier R.J., Park S., Leppla S.H.et al. Crystal structure of the anthrax lethal factor. Nature. 414:2001;229-233.
10. Drum C.L., Yan S.Z., Bard J., Shen Y.Q., Lu D., Soelaiman S., Grabarek Z., Bohm A., Tang W.J. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature. 415:2002;396-402.
11. Bradley K.A., Mogridge J., Mourez M., Collier R.J., Young J.A. Identification of the cellular receptor for anthrax toxin. Nature. 414:2001;225-229.
12. Scobie H.M., Rainey G.J., Bradley K.A., Young J.A. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S A. 100:2003;5170-5174 Identification of the second major receptor for anthrax toxin.
13. Abrami L., Liu S., Cosson P., Leppla S.H., van der Goot F.G. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol. 160:2003;321-328 Characterization of the anthrax toxin uptake pathway and identification of lipid raft involvement in the toxin endocytosis.
14. Liu S., Leppla S.H. Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J Biol Chem. 278:2003;5227-5234.
15. Rosovitz M.J., Schuck P., Varughese M., Chopra A.P., Mehra V., Singh Y., McGinnis L.M., Leppla S.H. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem. 278:2003;30936-30944.
16. Mogridge J., Mourez M., Collier R.J. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J Bacteriol. 183:2001;2111-2116.
17. Mogridge J., Cunningham K., Collier R.J. Stoichiometry of anthrax toxin complexes. Biochemistry. 41:2002;1079-1082.
18. Cunningham K., Lacy D.B., Mogridge J., Collier R.J. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc Natl Acad Sci U S A. 99:2002;7049-7053.
19. Mogridge J., Cunningham K., Lacy D.B., Mourez M., Collier R.J. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc Natl Acad Sci U S A. 99:2002;7045-7048.
20. Lacy D.B., Mourez M., Fouassier A., Collier R.J. Mapping the anthrax protective antigen binding site on the lethal and edema factors. J Biol Chem. 277:2002;3006-3010.
21. Ahuja N., Kumar P., Bhatnagar R. Hydrophobic residues Phe552, Phe554, Ile562, Leu566, and Ile574 are required for oligomerization of anthrax protective antigen. Biochem Biophys Res Commun. 287:2001;542-549.
22. Kumar P., Ahuja N., Bhatnagar R. Purification of anthrax edema factor from Escherichia coli and identification of residues required for binding to anthrax protective antigen. Infect Immun. 69:2001;6532-6536.
23. Chauhan V., Bhatnagar R. Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor. Infect Immun. 70:2002;4477-4484.
24. Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J. 352:2000;739-745.
25. Tonello F, Ascenzi P, Montecucco C: The metalloproteolytic activity of the anthrax lethal factor is substrate-inhibited. J Biol Chem 2003. Advance e-pub.
26. Chopra A.P., Boone S.A., Liang X., Duesbery N.S. Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J Biol Chem. 278:2003;9402-9406.
27. Ezzell J.W., Welkos S.L. The capsule of Bacillus anthracis, a review. J Appl Microbiol. 87:1999;250.
28. Makino S., Watarai M., Cheun H.I., Shirahata T., Uchida I. Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax. J Infect Dis. 186:2002;227-233.
29. Saile E., Koehler T.M. Control of anthrax toxin gene expression by the transition state regulator abrB. J Bacteriol. 184:2002;370-380.
30. Koehler T.M. Bacillus anthracis genetics and virulence gene regulation. Curr Top Microbiol Immunol. 271:2002;143-164.
31. Bourgogne A., Drysdale M., Hilsenbeck S.G., Peterson S.N., Koehler T.M. Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun. 71:2003;2736-2743.
32. Mignot T., Mock M., Fouet A. A plasmid-encoded regulator couples the synthesis of toxins and surface structures in Bacillus anthracis. Mol Microbiol. 47:2003;917-927.
33. Ross J.M. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol. 73:1957;485-494.
34. Guidi-Rontani C., Weber-Levy M., Labruyere E., Mock M. Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol. 31:1999;9-17.
35. Barnes J.M. The development of anthrax following administration of spore by inhalation. Br J Exp Pathol. 28:1947;385-394.
36. Dixon T.C., Fadl A.A., Koehler T.M., Swanson J.A., Hanna P.C. Early Bacillus anthracis-macrophage interactions: intracellular survival and escape. Cell Microbiol. 2:2000;453-463.
37. Guidi-Rontani C., Levy M., Ohayon H., Mock M. Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol Microbiol. 42:2001;931-938.
38. Welkos S., Friedlander A., Weeks S., Little S., Mendelson I. In vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J Med Microbiol. 51:2002;821-831 A study characterizing the role of toxin in spore uptake.
39. Welkos S., Little S., Friedlander A., Fritz D., Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology. 147:2001;1677-1685.
40. Guidi-Rontani C., Weber-Levy M., Labruyere E., Mock M. Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol. 31:1999;9-17.
41. Stepanov A.V., Marinin L.I., Pomerantsev A.P., Staritsin N.A. Development of novel vaccines against anthrax in man. J Biotechnol. 44:1996;155-160.
42. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., Gibbs P., Dertzbaugh M., Friedlander A.M. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine. 19:2001;4768-4773.
43. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D.et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 280:1998;734-737.
44. Vitale G., Pellizzari R., Recchi C., Napolitani G., Mock M., Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun. 248:1998;706-711.
45. Welkos S.L., Keener T.J., Gibbs P.H. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun. 51:1986;795-800.
46. Roberts J.E., Watters J.W., Ballard J.D., Dietrich W.F. Ltx1, a mouse locus that influences the susceptibility of macrophages to cytolysis caused by intoxication with Bacillus anthracis lethal factor, maps to chromosome 11. Mol Microbiol. 29:1998;581-591.
47. Hanna P.C., Acosta D., Collier R.J. On the role of macrophages in anthrax. Proc Natl Acad Sci U S A. 90:1993;10198-10201.
48. Ezzell J.W., Ivins B.E., Leppla S.H. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect Immun. 45:1984;761-767.
49. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., Tapper M., Fisk T.L., Zaki S., Popovic T.et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 7:2001;933-944.
50. Borio L., Frank D., Mani V., Chiriboga C., Pollanen M., Ripple M., Ali S., DiAngelo C., Lee J., Arden J.et al. Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA. 286:2001;2554-2559.
51. Mayer T.A., Bersoff-Matcha S., Murphy C., Earls J., Harper S., Pauze D., Nguyen M., Rosenthal J., Cerva D. Jr., Druckenbrod G.et al. Clinical presentation of inhalational anthrax following bioterrorism exposure: report of 2 surviving patients. JAMA. 286:2001;2549-2553.
52. Earls J.P., Cerva D. Jr., Berman E., Rosenthal J., Fatteh N., Wolfe P.P., Clayton R., Murphy C., Pauze D., Mayer T.et al. Inhalational anthrax after bioterrorism exposure: spectrum of imaging findings in two surviving patients. Radiology. 222:2002;305-312.
53. Park J.M., Greten F.R., Li Z.W., Karin M. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science. 297:2002;2048-2051 The first report of sensitization of resistant mouse macrophages to anthrax lethal toxin-mediated apoptosis.
54. Kim S.O., Jing Q., Hoebe K., Beutler B., Duesbery N.S., Han J. Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alpha. J Biol Chem. 278:2003;7413-7421 The first report of sensitization of resistant mouse macrophages to anthrax lethal toxin-mediated necrosis.
55. Watters J.W., Dewar K., Lehoczky J., Boyartchuk V., Dietrich W.F. Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor. Curr Biol. 11:2001;1503-1511.
56. Pellizzari R., Guidi-Rontani C., Vitale G., Mock M., Montecucco C. Lethal factor of Bacillus anthracis cleaves the N-terminus of MAPKKs: analysis of the intracellular consequences in macrophages. Int J Med Microbiol. 290:2000;421-427.
57. Tang G., Leppla S.H. Proteasome activity is required for anthrax lethal toxin to kill macrophages. Infect Immun. 67:1999;3055-3060.
58. Popov S.G., Villasmil R., Bernardi J., Grene E., Cardwell J., Popova T., Wu A., Alibek D., Bailey C., Alibek K. Effect of Bacillus anthracis lethal toxin on human peripheral blood mononuclear cells. FEBS Lett. 527:2002;211-215.
59. Lincoln R.E., Walker J.S., Klein F., Rosenwald A.J., Jones W.I. Jr. Value of field data for extrapolation in anthrax. Fed Proc. 26:1967;1558-1562.
60. Pellizzari R., Guidi-Rontani C., Vitale G., Mock M., Montecucco C. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett. 462:1999;199-204.
61. Erwin J.L., DaSilva L.M., Bavari S., Little S.F., Friedlander A.M., Chanh T.C. Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect Immun. 69:2001;1175-1177.
62. Agrawal A., Lingappa J., Leppla S.H., Agrawal S., Jabbar A., Quinn C., Pulendran B. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature. 424:2003;329-334 The first report showing in vivo impact of anthrax lethal toxin on acquired immunity.
63. Webster J.I., Tonelli L.H., Moayeri M., Simons S.S. Jr., Leppla S.H., Sternberg E.M. Anthrax lethal factor represses glucocorticoid and progesterone receptor activity. Proc Natl Acad Sci U S A. 100:2003;5706-5711 The first report showing lethal toxin intervention in glucocorticoid signaling.
64. Hoover D.L., Friedlander A.M., Rogers L.C., Yoon I.K., Warren R.L., Cross A.S. Anthrax edema toxin differentially regulates lipopolysaccharide- induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect Immun. 62:1994;4432-4439.
65. O'Brien J., Friedlander A., Dreier T., Ezzell J., Leppla S. Effects of anthrax toxin components on human neutrophils. Infect Immun. 47:1985;306-310.
66. Vasconcelos D., Barnewall R., Babin M., Hunt R., Estep J., Nielsen C., Carnes R., Carney J. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Invest. 83:2003;1201-1209 The first complete pathology analysis of anthrax infected primates.
67. Guarner J., Jernigan J.A., Shieh W.J., Tatti K., Flannagan L.M., Stephens D.S., Popovic T., Ashford D.A., Perkins B.A., Zaki S.R. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol. 163:2003;701-709 Pathology report of anthrax infected humans. Important historic perspective on anthrax toxin studies.
68. Grinberg L.M., Abramova F.A., Yampolskaya O.V., Walker D.H., Smith J.H. Quantitative pathology of inhalational anthrax I: quantitative microscopic findings. Mod Pathol. 14:2001;482-495.
69. Abramova F.A., Grinberg L.M., Yampolskaya O.V., Walker D.H. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A. 90:1993;2291-2294.
70. Smith H. Discovery of the anthrax toxin: the beginning of studies of virulence determinants regulated in vivo. Int J Med Microbiol. 291:2002;411-417.
71. Smith H. Discovery of the anthrax toxin: the beginning of in vivo studies on pathogenic bacteria. Trends Microbiol. 8:2000;199-200.